1-3 of 3
Gregory I. Berk, MD
Close
Sort by
Journal Articles

Inhibiting PIM-1 Is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target.

Valerie I. Brown, MD, PhD, Cecilia Sheen, Jessica Hulitt, Theresa Ryan, Laura DiNardo, David Barrett, MD, PhD, David T. Teachey, MD, David J. Bearss, PhD, Gregory I. Berk, MD, Stephan A. Grupp, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 1922.
https://doi.org/10.1182/blood.V112.11.1922.1922
Published: 2008
Journal Articles

A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.

Francis Giles, MD, David A. Rizzieri, MD, Solly George, RN, Wendy Stock, MD, Jeannie Fontanilla, BS, Gavin S. Choy, PharmD, Gregory I. Berk, MD
Journal: Blood
Blood (2006) 108 (11): 1968.
https://doi.org/10.1182/blood.V108.11.1968.1968
Published: 2006
Journal Articles

Phase I Trial of Sphingosomal Vincristine (SV, Marqibo®) and Dexamethasone in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL).

Deborah A. Thomas, MD, Hagop M. Kantarjian, MD, Leonard Heffner, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Stefan Faderl, MD, Alessandra Ferrajoli, MD, Francis Giles, MD, William Wierda, MD, Farhad Ravandi-Kashani, MD, Gavin Choy, PharmD, Gregory I. Berk, MD, Susan O’Brien, MD
Journal: Blood
Blood (2006) 108 (11): 4539.
https://doi.org/10.1182/blood.V108.11.4539.4539
Published: 2006